Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 millionAdvancement of ZORYVE ...
Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback